Sierra Internal Medicine

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

Sierra Internal Medicine is a clinic in Incline Village, Nevada, United States that treats ME/CFS patients, and takes part in research into ME/CFS.[1]

Ampligen[edit | edit source]

Sierra Internal Medicine, along with North Carolina's Hunter-Hopkins Center are the two primary clinics conducting clinical trials into Ampligen (rintatolimod) for severe ME/CFS. Ampligen is available under the compassionate use program.[1]

MCAM[edit | edit source]

Sierra Internal Medicine is also taking part in the CDC's Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome or MCAM.[2][3]

Daniel Peterson[edit | edit source]

The 1984 Incline Village chronic fatigue syndrome outbreak affected many patients in the Incline Village area. Since that date, Dr Daniel L. Peterson, began specializing in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).[4][5][6] Dr Peterson continues to be a leader in ME/CFS treatment and research and serves on the Scientific Advisory Boards at Simmaron Research, the Faculty of Health Sciences and Medicine at Griffith University in Queensland, Australia, and the Open Medicine Foundation.[7][8] He has been based at Sierra Internal Medicine since 2010.[9]

Contact details[edit | edit source]

Sierra Internal Medicine
Incline Village
Nevada
United States 89451
  • Phone: 775-831-4818
  • Email: bbjorke@simmaron.com   

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.01.1 "Ampligen in Chronic Fatigue Syndrome". ClinicalTrials.gov. Retrieved August 13, 2018.
  2. Bateman, L.; Darakjy, S.; Klimas, N.; Peterson, D.; Levine, S.M.; Allen, A.; Carlson, S.A.; Balbin, E.G.; Gottschalk, G.; March, D. (2015). "Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study". Fatigue: Biomedicine, Health & Behavior. 3 (1): 1-15. doi:10.1080/21641846.2014.978109.
  3. Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017). "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study". American Journal of Epidemiology. 1–10. doi:10.1093/aje/kwx029.
  4. "Dr. Dan Peterson (Sierra Internal Medicine, Incline Village, Nevada) - Health Rising". Health Rising. Retrieved August 13, 2018.
  5. Strayer, DR; Carter, W; Strauss, KI; Brodsky, I; Suhadolnik, R; Ablashi, D; Henry, B; Mitchell, WM; Bastien, S; Peterson, D (1995). "Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen". Journal of Chronic Fatigue Syndrome. 1 (1): 35-53. doi:10.1300/J092v01n01_04.
  6. Strayer, DR; Carter, WA; Stouch, BC; Stevens, SR; Bateman, L; Cimoch, PJ; Lapp, CW; Peterson, DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell, WM (2012). "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome". PLoS One. 7 (3): e31334. doi:10.1371/journal.pone.0031334. PMID 22431963.
  7. "Daniel L. Peterson, MD". Open Medicine Foundation. Retrieved April 1, 2019.
  8. "Collaborators - Simmaron Research". Simmaron Research. Retrieved August 13, 2018.
  9. "History of Changes for Study: NCT00215813 | Study of Ampligen in Chronic Fatigue Syndrome". ClinicalTrials.gov. April 8, 2010. Retrieved April 13, 2020.

Centers for Disease Control and Prevention (CDC) - The Centers for Disease Control and Prevention is a U.S. government agency dedicated to epidemiology and public health. It operates under the auspices of the Department of Health and Human Services.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

double blinded trial A clinical trial is double blinded if neither the participants nor the researchers know which treatment group they are allocated to until after the results are interpreted. This reduces bias. (Learn more: www.nottingham.ac.uk)

agonist A chemical that binds to the receptor and stimulates it's function, e.g., morphine is an opioid agonist that binds to the opioid receptor, reducing pain. The opposite of an antagonist.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.